Seeking out great stocks to buy is essential, but many would say it’s even more important to know which stocks to steer clear of. A losing stock can eat away at your precious long-term returns. So, figuring out which stocks to trim or get rid of is essential for proper portfolio maintenance.
Even the best gardens need pruning, and our team has spotted a few stocks that seem like prime candidates for selling or avoiding. Continue reading to find out which three stocks our team is staying away from this week.
The U.S. Economy is headed for trouble…
Why are stocks absolutely soaring right now…? Yet at the same time millions of Americans are out of work… Commercial bankruptcies are piling up… Delinquent credit card debt is skyrocketing… Not to mention, we are smack in the middle of a pandemic that has all but forced our economy to a grinding halt… Something’s just not adding up. Friend, if you are confused by all of this… You are not alone… [Full Story]
Communications software company Everbridge (EVBG) made it to our list this week after the release of dismal 2022 guidance and the announcement of a poorly timed change in management. The company announced the resignation of CEO David Meredith and gave no explanation for him unexpectedly giving up his seat. In the interim, Everbridge’s CFO and VP Patrick Brickly and CRO Vernon Irvin will act as Co-Ceo’s until a permanent replacement is found.
BofA analyst Brad Sills downgraded Everbridge to Underperform from Neutral with a price target of $100, down from $175. The analyst cites the company’s announcement of the transition of its CEO. “The CFO and CRO of Everbridge are capable executives, but the CEO transition creates an overhang and also puts into question the overall future direction of the business,” Sills tells investors in a research note.
Everbridge also offered an initial look into revenue guidance for 2022. The company sees 20%-23% growth, well below Wall Street expectations. With growth decelerating 36% in 2021 to 23% in 2022, there are a lot of unanswered questions that management has yet to address.
JPMorgan analyst Sterling Auty also downgraded EVBG to Neutral from Overweight with a price target of $127, down from $200. The analyst believes the new 2022 growth guidance is likely to further solidify growth deceleration concerns, “especially with the possibility of disruption from the leadership change.”
The stock was also downgraded at Baird, Needham, Barclays, and Northland. Until further developments regarding the management shift surface, we’ll stay away from this stock.
TRUE MARKET INSIDERS:
Warning: Move Your Money ASAP
The clock just started on the biggest stock market event in twenty years. And the next couple months could determine who will become extremely wealthy in 2022 – and who won’t. [Full Story…]
Stay-at-home culture lifted PTON to great heights throughout 2020, surging above $160 during last year’s holiday season. Sadly, the past year has not been kind to Peloton as reopening headwinds seem to have been too much for the company to handle. The company’s failure to execute amid growing competition in the space has dragged share price down nearly 75% this year.
A large part of that loss came after the company reported a steep revenue miss during its recent earnings call. The consensus was looking for $1.51 billion in revenue for the first quarter and $5.4 billion for fiscal 2021. The reported figures fell short, further disappointing investors. Peloton reported $1.1 – $1.2 billion in revenue for the first quarter and $4.4 – $4.8 billion for FY21. The company attributed its lackluster performance to a greater than expected tapering in retail visits and website traffic.
To make matters worse, Peloton’s outlook for FY22 was less than rosy. The company said that the supply chain crisis and higher freight costs led them to lower guidance for the year. The company further stated that its team has never seen a more complex operating environment in which to guide or expect results. Hardware margins are seeing compression from supply chain and logistics issues limiting visibility into future performance. The company lowered FY22 revenue guidance initially provided last quarter by $800 million.
Peloton has been downgraded at several firms and its price target slashed. Stifel analyst Scott Devitt downgraded Peloton to Hold from Buy with a price target of $70, down from $120. The analyst says the company’s fiscal year outlook has seen “rapid deterioration.”
PTON share price has bled 63% over the past 6 months, which could pique the interest of bargain hunters. We’ll stick to the sidelines until there is evidence to validate the already pricey valuation.
Tesla’s Worst Nightmare
The tiny, little-known stock behind the “Tesla Killer” trades for just a few bucks. [Full Story…]
Last up is offshore oil rig service provider Transocean (RIG) suffered badly in the wake of 2020’s economic shutdown and travel bans (when crude prices plummeted to all-time lows), but the company was in bad shape long before that. In 2019 prior to the pandemic, Transocean reported an EPS loss of $1.45.
Bank of America analyst Mike Sabella projects that losses will continue through at least 2023. He’s projecting Transocean will finish 2021 with about $450 million in liquidity, and the company will generate negative $50 million in 2022 free cash flow. Bank of America has an Underperform rating and a $1 price target for Transocean. Since Transocean has more than $8 billion in debt and $600 million in 2022 debt maturities, Sabella’s forecast doesn’t seem unrealistic.
The current consensus among the 15 analysts offering recommendations is to Hold RIG. The stock has 9 Hold ratings, 3 Sell ratings, and 1 Buy rating.
New in Biotech:
The Guardian: “New pill could spell the end of all disease.”
This pill is set to completely change the lives of millions of Americans.
And because just one tiny Brisbane company has virtually monopolized this technology with 140 foolproof patents…
Investors who get in on the ground floor stand to become rich beyond their wildest dreams. [Full Story…]